Stockscreener 앱 받기
8.18
0.99%
0.08
시간 외 거래:
8.18
전일 마감가:
$8.10
열려 있는:
$8.05
하루 거래량:
808.95K
Relative Volume:
0.62
시가총액:
$1.05B
수익:
$175.51M
순이익/손실:
$-78.02M
주가수익비율:
-15.43
EPS:
-0.53
순현금흐름:
$-34.18M
1주 성능:
+5.55%
1개월 성능:
-5.65%
6개월 성능:
+16.03%
1년 성능:
+67.97%
1일 변동 폭
$7.97
$8.21
1주일 범위
$7.65
$8.32
52주 변동 폭
$4.86
$10.67
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
명칭
Aurinia Pharmaceuticals Inc
전화
250-744-2487
주소
#140, 14315 - 118 AVENUE, EDMONTON, BC
AUPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
8.18 | 1.05B | 175.51M | -78.02M | -34.18M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-11-04 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-05-05 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-25 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-05-05 | 개시 | Cowen | Outperform |
| 2020-01-10 | 개시 | Jefferies | Buy |
| 2019-12-16 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-16 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-02-08 | 개시 | RBC Capital Mkts | Outperform |
| 2017-10-30 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-03-22 | 재확인 | FBR & Co. | Outperform |
| 2016-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2016-06-30 | 개시 | H.C. Wainwright | Buy |
| 2015-05-08 | 개시 | MLV & Co | Buy |
모두보기
Aurinia Pharmaceuticals Inc 주식(AUPH)의 최신 뉴스
Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth (NASDAQ:AUPH) - Seeking Alpha
Press Release Distribution & PR Platform - ACCESS Newswire
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Zacks Investment Research
Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting - Business Wire
Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet - MSN
Aurinia Sues Galenicum to Block Copies of Lupkynis Kidney Drug - Bloomberg Law News
Aurinia Sues Lotus Alleging Lupus Drug Patent Infringement - Law360
High Growth Tech Stocks To Watch In The US Market - simplywall.st
Declining Stock and Decent Financials: Is The Market Wrong About Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)? - Yahoo
Little Excitement Around Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Revenues - simplywall.st
Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March - Insider Monkey
(AUPH) Trading Signals - news.stocktradersdaily.com
Insiders Are Spending Big: 15 Stocks Leading in March - Insider Monkey
Aurinia Pharmaceuticals Announces Financial Growth and Pipeline Progress in 2024 - Zenopa
Principal Financial Group Inc. Sells 1,325 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Aurinia Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome - marketscreener.com
Aurinia Pharmaceuticals’ chief medical officer sells shares worth $68,350 - Investing.com India
Aurinia Pharmaceuticals’ chief medical officer sells shares worth $68,350 By Investing.com - Investing.com UK
Commit To Purchase Aurinia Pharmaceuticals At $7, Earn 17.4% Annualized Using Options - Nasdaq
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings May Just Be The Starting Point - Yahoo Finance
Aurinia Pharmaceuticals stock climbs on insider buying - MSN
Aurinia Pharmaceuticals CEO Peter Greenleaf sells shares worth $2.87 million - Investing.com India
Aurinia Pharmaceuticals CFO Joseph Miller sells shares worth $939,611 - Investing.com Australia
Aurinia Pharmaceuticals COO Donley sells shares worth $994,424 By Investing.com - Investing.com Canada
Aurinia Pharmaceuticals CFO Joseph Miller sells shares worth $939,611 By Investing.com - Investing.com South Africa
Major Investment Alert: Kevin Tang Boosts Stake in Aurinia Pharmaceuticals - TipRanks
Aurinia Pharmaceuticals’ chief medical officer sells $97,912 in stock - Investing.com
Aurinia Pharmaceuticals COO Donley sells shares worth $994,424 - Investing.com India
Aurinia Pharmaceuticals EVP Stephen Robertson sells shares worth $975,223 - Investing.com
Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock? - Nasdaq
Objective long/short (AUPH) Report - Stock Traders Daily
LAWSUITS FILED AGAINST ABBV, SDIG and AUPHJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
Atria Wealth Solutions Inc. Buys Shares of 15,000 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Results: Aurinia Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - Simply Wall St
Results: Aurinia Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo
IFP Advisors Inc Raises Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Sees Strong Trading Volume Following Strong Earnings - MarketBeat
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2024 Earnings Call Transcript - Insider Monkey
Aurinia Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Regulatory and Financial Challenges Loom for Aurinia Pharmaceuticals Despite FDA and EC Approvals - TipRanks
Aurinia Pharmaceuticals Reports Strong 2024 Financial Growth - TipRanks
Aurinia Pharmaceuticals Reports Balanced Earnings with Growth and Challenges - TipRanks
Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations - Benzinga
Aurinia: Q4 Earnings Snapshot - CT Insider
Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates - MSN
Earnings call transcript: Aurinia Pharmaceuticals Q4 2024 misses EPS forecast - Investing.com
Aurinia Pharmaceuticals Inc (AUPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):